Review of NICE Technology Appraisal Guidance No.158; Oseltamivir, amantadine and zanamivir for the prophylaxis of influenza, and No.168; Amantadine, oseltamivir and zanamivir for the treatment of influenza

Proposal to move the existing guidance to the static list (additional consultation)

In November 2013 we consulted on our plans to move TA168 to the static list of Technology Appraisals. Consultees and commentators were generally supportive of this recommendation (Appendix C is a table showing all of the comments received during the consultation period). TA158 was added to the static list in November 2011.

In April 2014, the Cochrane collaboration published its update to the systematic review for oseltamivir and zanamivir for preventing and treating influenza in healthy adults and children.

Having considered the results of the Cochrane update, we believe that is unlikely to change the recommendations made for TA158 and TA168, and that TA158 should remain on the static list, and TA168 should be added to the static list, as originally proposed.

Topics on the static list may be transferred back to the active list for further consideration if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to provide their comments on the updated proposal and to inform us of any evidence which will help us decide the best way to update this guidance.  Please see appendix A for a full list of the organisations we have contacted. 

June 2014

Attachments